A genius approach to 400M tons of plastic

The Flash Report

06 Mar 2026 — 1 min read

Over 400 million tons of plastic are produced every year. Most of it ends up in landfills, where it can take centuries to break down.

Midori Bio believes that waste can become a resource.

Its proprietary Advanced BioRecycle™ technology helps plastic break down up to 64x faster, converting landfill waste into biogas that can be captured and used as clean energy. And that’s creating major opportunities for investors.

Unlike many sustainability solutions, Midori’s technology does not require factories to change how plastic is produced. It integrates directly into existing manufacturing processes without new equipment or capital investment.

That is why major global brands are already adopting the technology.

Companies like HEAD/PENN Tennis, KEEN Footwear, and Planters are incorporating Midori Bio’s solution as they work toward their environmental commitments.

And these early partnerships highlight how Midori Bio is building a scalable platform for plastic circularity:

Adoption: Global brands are already integrating Midori Bio’s technology into products ranging from tennis balls to footwear and consumer packaging.
Compatibility: The additive works within existing plastic manufacturing processes, allowing companies to adopt the solution without operational disruption.
Opportunity: Until March 12, Midori invites retail investors to join before their share price changes.

This is only the beginning, too. With plastic production projected to triple by 2060, demand for solutions like this only figures to increase.

Midori Bio is currently in discussions with 150+ additional potential partners exploring how its technology could be implemented across new industries and consumer products.

And investors have the opportunity to participate in that expansion.

Become a Midori Bio shareholder before the share price changes on March 12.

This is a paid advertisement for Midori Bio's Regulation A offering. Please read the offering circular at https://invest.midori-bio.com/

The Biggest Unsolved Problem in Medicine?

Today, over half a billion people battle osteoarthritis. Each year, they spend $240B trying to halt the destruction of joint cartilage. But no cure exists on the market. Not for lack of trying, either. Big Pharma’s spent billions failing. Thankfully, Cytonics may have cracked the code. They discovered the

What if David and Goliath teamed up instead?

That’s what’s currently playing out in the foodservice industry, where industry goliaths Sodexo, Aramark, and Compass Group all partnered with foodtech startup Automated Retail Technologies. Why did they choose ART? With more than 150,000 venues managed by that trio alone, staffing overnight operations is costly and complicated.

The Key to This $500B Market Is in Your Bloodstream

Every year, $240B is spent on treating the symptoms of osteoarthritis, a disease that leads to joint degradation and, eventually, immobility. With 500M people afflicted, its total addressable market is worth over $500B. But not a single therapy has been able to actually stop it. The answer, it turns out,

Superhuman' Pre-IPO Stock Trading Under $1

Have you heard about this sub $1 Pre-IPO company that is making people "Superhumans"? It's all thanks to their new product called Visor. And it's very similar to Jarvis from the movie Iron Man. Investors are calling this a 'massive breakthrough'. But

Read more

The Biggest Unsolved Problem in Medicine?

What if David and Goliath teamed up instead?

The Key to This $500B Market Is in Your Bloodstream

Superhuman' Pre-IPO Stock Trading Under $1